Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 1/2015

01-07-2015

Reproducibility over time and effect of low-dose aspirin on soluble P-selectin and soluble CD40 ligand

Authors: Vanessa Valdes, Michael A. Nardi, Lindsay Elbaum, Jeffrey S. Berger

Published in: Journal of Thrombosis and Thrombolysis | Issue 1/2015

Login to get access

Abstract

Platelet markers [soluble CD40 ligand (sCD40L) and soluble p selectin (sPselectin)] are associated with platelet activation and cardiovascular events. We sought to investigate the reproducibility of these markers over time and the effect of low-dose aspirin on sCD40L and sPselectin in plasma and serum. Following an overnight fast, 40 healthy volunteers had weekly phlebotomy and were administered aspirin 81 mg/day between weeks 3 and 4. Reproducibility over time was assessed by coefficient of variation (CV) and inter-class correlation coefficient. Correlation between markers was assessed using Pearson r statistic. Difference between levels pre- and post-aspirin was measured with Wilcoxon signed-rank test. Data are presented as median (interquartile range). sCD40L and sPselectin measurements were reproducible over time in plasma and serum (CV < 10 %). Measurement of sCD40L and sPselectin in plasma correlated with levels in serum before aspirin and after aspirin. There was no significant correlation between sCD40L and sPselectin. After 1-week of aspirin 81 mg/day, there was a reduction in sCD40L and sPselectin in serum and plasma, respectively. Soluble CD40L and sPselectin are independent markers that are reproducible over time in both plasma and sera and are reduced by 1-week of low-dose aspirin.
Appendix
Available only for authorised users
Literature
1.
go back to reference Blann AD, Lip GY (1997) Hypothesis: is soluble P-selectin a new marker of platelet activation? Atherosclerosis 128:135–138CrossRefPubMed Blann AD, Lip GY (1997) Hypothesis: is soluble P-selectin a new marker of platelet activation? Atherosclerosis 128:135–138CrossRefPubMed
2.
go back to reference Sharma G, Berger JS (2011) Platelet activity and cardiovascular risk in apparently healthy individuals: a review of the data. J Thromb Thrombolysis 32:201–208CrossRefPubMed Sharma G, Berger JS (2011) Platelet activity and cardiovascular risk in apparently healthy individuals: a review of the data. J Thromb Thrombolysis 32:201–208CrossRefPubMed
3.
go back to reference Antoniades C, Bakogiannis C, Tousoulis D, Antonopoulos AS, Stefanadis C (2009) The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J Am Coll Cardiol 54:669–677CrossRefPubMed Antoniades C, Bakogiannis C, Tousoulis D, Antonopoulos AS, Stefanadis C (2009) The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J Am Coll Cardiol 54:669–677CrossRefPubMed
4.
go back to reference Burger PC, Wagner DD (2003) Platelet P-selectin facilitates atherosclerotic lesion development. Blood 101:2661–2666CrossRefPubMed Burger PC, Wagner DD (2003) Platelet P-selectin facilitates atherosclerotic lesion development. Blood 101:2661–2666CrossRefPubMed
5.
6.
go back to reference Ridker PM, Buring JE, Rifai N (2001) Soluble P-selectin and the risk of future cardiovascular events. Circulation 103:491–495CrossRefPubMed Ridker PM, Buring JE, Rifai N (2001) Soluble P-selectin and the risk of future cardiovascular events. Circulation 103:491–495CrossRefPubMed
7.
go back to reference Schonbeck U, Varo N, Libby P, Buring J, Ridker PM (2001) Soluble CD40L and cardiovascular risk in women. Circulation 104:2266–2268CrossRefPubMed Schonbeck U, Varo N, Libby P, Buring J, Ridker PM (2001) Soluble CD40L and cardiovascular risk in women. Circulation 104:2266–2268CrossRefPubMed
8.
go back to reference Shah B, Valdes V, Nardi MA, Hu L, Schrem E, Berger JS (2014) Mean platelet volume reproducibility and association with platelet activity and anti-platelet therapy. Platelets 25:188–192CrossRefPubMedCentralPubMed Shah B, Valdes V, Nardi MA, Hu L, Schrem E, Berger JS (2014) Mean platelet volume reproducibility and association with platelet activity and anti-platelet therapy. Platelets 25:188–192CrossRefPubMedCentralPubMed
9.
go back to reference Chu SG, Becker RC, Berger PB et al (2010) Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. J Thromb Haemost 8:148–156CrossRefPubMedCentralPubMed Chu SG, Becker RC, Berger PB et al (2010) Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. J Thromb Haemost 8:148–156CrossRefPubMedCentralPubMed
10.
go back to reference Thom J, Gilmore G, Yi Q, Hankey GJ, Eikelboom JW (2004) Measurement of soluble P-selectin and soluble CD40 ligand in serum and plasma. J Thromb Haemost 2:2067–2069CrossRefPubMed Thom J, Gilmore G, Yi Q, Hankey GJ, Eikelboom JW (2004) Measurement of soluble P-selectin and soluble CD40 ligand in serum and plasma. J Thromb Haemost 2:2067–2069CrossRefPubMed
11.
go back to reference Mason PJ, Chakrabarti S, Albers AA et al (2005) Plasma, serum, and platelet expression of CD40 ligand in adults with cardiovascular disease. Am J Cardiol 96:1365–1369CrossRefPubMed Mason PJ, Chakrabarti S, Albers AA et al (2005) Plasma, serum, and platelet expression of CD40 ligand in adults with cardiovascular disease. Am J Cardiol 96:1365–1369CrossRefPubMed
12.
go back to reference Iversen LH (1997) Pre-analytical variation in the measurements of sensitive markers of coagulation and fibrinolysis: the influence of venipuncture and mixing of blood. Haemostasis 27:119–124PubMed Iversen LH (1997) Pre-analytical variation in the measurements of sensitive markers of coagulation and fibrinolysis: the influence of venipuncture and mixing of blood. Haemostasis 27:119–124PubMed
13.
go back to reference Lee RD, Barcel DA, Williams JC et al (2012) Pre-analytical and analytical variables affecting the measurement of plasma-derived microparticle tissue factor activity. Thromb Res 129:80–85CrossRefPubMedCentralPubMed Lee RD, Barcel DA, Williams JC et al (2012) Pre-analytical and analytical variables affecting the measurement of plasma-derived microparticle tissue factor activity. Thromb Res 129:80–85CrossRefPubMedCentralPubMed
14.
go back to reference Ahn ER, Lander G, Jy W et al (2004) Differences of soluble CD40L in sera and plasma: implications on CD40L assay as a marker of thrombotic risk. Thromb Res 114:143–148CrossRefPubMed Ahn ER, Lander G, Jy W et al (2004) Differences of soluble CD40L in sera and plasma: implications on CD40L assay as a marker of thrombotic risk. Thromb Res 114:143–148CrossRefPubMed
15.
go back to reference Varo N, Nuzzo R, Natal C, Libby P, Schonbeck U (2006) Influence of pre-analytical and analytical factors on soluble CD40L measurements. Clin Sci 111:341–347CrossRefPubMed Varo N, Nuzzo R, Natal C, Libby P, Schonbeck U (2006) Influence of pre-analytical and analytical factors on soluble CD40L measurements. Clin Sci 111:341–347CrossRefPubMed
16.
go back to reference Riondino S, Martini F, La Farina F, Spila A, Guadagni F, Ferroni P (2010) Increased plasma levels of soluble CD40 ligand correlate with platelet activation markers and underline the need for standardized pre-analytical conditions. Clin Biochem 43:666–670CrossRefPubMed Riondino S, Martini F, La Farina F, Spila A, Guadagni F, Ferroni P (2010) Increased plasma levels of soluble CD40 ligand correlate with platelet activation markers and underline the need for standardized pre-analytical conditions. Clin Biochem 43:666–670CrossRefPubMed
17.
go back to reference Ferroni P, Martini F, Riondino S et al (2009) Soluble P-selectin as a marker of in vivo platelet activation. Clin Chim acta; Int J Clin Chem 399:88–91CrossRef Ferroni P, Martini F, Riondino S et al (2009) Soluble P-selectin as a marker of in vivo platelet activation. Clin Chim acta; Int J Clin Chem 399:88–91CrossRef
18.
go back to reference Chen M, Geng JG (2006) P-selectin mediates adhesion of leukocytes, platelets, and cancer cells in inflammation, thrombosis, and cancer growth and metastasis. Archivum immunologiae et therapiae experimentalis 54:75–84CrossRefPubMed Chen M, Geng JG (2006) P-selectin mediates adhesion of leukocytes, platelets, and cancer cells in inflammation, thrombosis, and cancer growth and metastasis. Archivum immunologiae et therapiae experimentalis 54:75–84CrossRefPubMed
19.
go back to reference Santilli F, Basili S, Ferroni P, Davi G (2007) CD40/CD40L system and vascular disease. Intern Emerg Med 2:256–268CrossRefPubMed Santilli F, Basili S, Ferroni P, Davi G (2007) CD40/CD40L system and vascular disease. Intern Emerg Med 2:256–268CrossRefPubMed
Metadata
Title
Reproducibility over time and effect of low-dose aspirin on soluble P-selectin and soluble CD40 ligand
Authors
Vanessa Valdes
Michael A. Nardi
Lindsay Elbaum
Jeffrey S. Berger
Publication date
01-07-2015
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 1/2015
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-015-1179-5

Other articles of this Issue 1/2015

Journal of Thrombosis and Thrombolysis 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine